IONSIonis Pharmaceuticals, Inc.

$63.37

The financials

Ionis Pharmaceuticals, Inc. by the numbers

Ionis Pharmaceuticals, Inc. (IONS) reported revenue of $268M in Q2 2026 (quarter ended June 30, 2026), down 41% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $115M. For the full year FY2025, revenue was $944M (+34% year on year) and net income −$381M. Its largest product in 2026-Q2 was Royalty at $76M, 28% of the disclosed total, just ahead of Spinraza Royalties at 19%.

Ionis Pharmaceuticals, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$268M$452M−41%
Gross profit$265M$448M−41%
Operating income−$102M$140Mto a loss
Net income−$115M$124Mto a loss
Diluted EPS−$0.69$0.70to a loss
Revenue by product, 2026-Q2, as reported to the SEC
ProductRevenueShare
Royalty$76M28%
Spinraza Royalties$53M19%
Salanersen$45M16%
DAWNZERA Sales$27M9.6%
Sapablursen$20M7.3%
Wainus Royalties$16M6.0%
Wainua Joint Development$16M5.9%
Other Commercial$12M4.2%
Other Royalties$6.0M2.2%
Tryngolza$4.6M1.7%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q2 2026Total $275.8M (+50%)
Wainus Royalties grew +58% year on yearTryngolza -76% year on year
  • Royalty$76.0MQoQ +30%year on year +8.6%
  • Spinraza Royalties$53.5MQoQ +22%year on year -1.6%
  • Salanersen$45.0MQoQ -year on year -
  • DAWNZERA Sales$26.6MQoQ +68%year on year -
  • Sapablursen$20.0MQoQ -year on year -
  • Wainus Royalties$16.4MQoQ +53%year on year +58%
  • Wainua Joint Development$16.2MQoQ -8.1%year on year +31%
  • Other Commercial$11.5MQoQ +76%year on year -15%
  • Other Royalties$6.0MQoQ +55%year on year +16%
  • Tryngolza$4.6MQoQ -83%year on year -76%
  • License Of Sapablursen-QoQ -year on year -
  • Other-QoQ -year on year -
  • Research And Development Services For Sapablursen-QoQ -year on year -
  • Tegsedi And Waylivra-QoQ -year on year -
Segment sum = 103% of reported consolidated revenue · Latest source: 10-Q filed 2026-07-29, SEC EDGAR